12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dacogen decitabine regulatory update

FDA issued a complete response letter for an sNDA from Eisai for Dacogen decitabine to treat acute myelogenous leukemia (AML) in patients 65 years and older. According to Eisai and partner Astex, FDA declined to approve the...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >